Related Experiment Video

Updated: May 3, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.0K

Linking oncogenesis and immune system evasion in acquired resistance to EGFR-targeting antibodies: Lessons from a

Greta Garrido1, Ailem Rabasa1, Belinda Sánchez1

  • 1Tumor Immunology Direction; Molecular Immunology Institute; Center of Molecular Immunology; Havana, Cuba.

Oncoimmunology
|February 6, 2014
PubMed

Insights

Identifying biomarkers for acquired resistance to epidermal growth factor receptor (EGFR) antibodies is key. Molecular changes in cancer pathways suggest combining targeted therapy with immunomodulatory drugs can overcome resistance.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Acquired resistance to epidermal growth factor receptor (EGFR)-targeting monoclonal antibodies limits treatment efficacy.
  • Understanding the molecular mechanisms of this resistance is crucial for improving patient outcomes.

Purpose of the Study:

  • To identify biomarkers associated with acquired resistance to EGFR-targeting monoclonal antibodies.
  • To explore potential therapeutic strategies to overcome this resistance.

Main Methods:

  • The study investigated molecular alterations in oncogenic and immunological pathways.
  • Analysis focused on mechanisms underlying insensitivity to EGFR-targeting therapies.

Main Results:

  • Molecular alterations in both oncogenic and immunological pathways were identified as potential drivers of resistance.
  • These findings highlight the complex interplay between cancer cell biology and the immune system in treatment response.

Conclusions:

  • Biomarkers associated with acquired resistance to EGFR-targeting monoclonal antibodies are critical for clinical application.
  • A combination approach using targeted anticancer agents and immunomodulatory drugs shows promise for overcoming acquired resistance.
Keywords:
EGFRMHCI alterationsacquired resistancemonoclonal antibodies

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

6.0K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.6K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

3.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K